) participated in the 32
annual J.P. Morgan Healthcare Conference. The presentation
focused on its strategic outlook and financial guidance for
Amicus' strategy is to advance the development of
next-generation Enzyme Replacement Therapies (ERTs). Amicus will
enter the clinic with lead programs in Fabry, Pompe and
mucopolysaccharidosis I (MPS I) in the year 2014, 2015 and 2016
respectively. The proof-of-concept preclinical data for
next-generation ERTs for Fabry and Pompe will be presented in the
first half of 2014.
Amicus expects cash, cash equivalents and marketable
securities of $82.0 million as of Dec 31, 2013. Amicus expects
2014 net cash spend in the range of $54 million to $59 million.
The company predicts that the current cash position should fund
operations into the second half of 2015.
) are conducting two phase III studies - FACETS Study and ATTRACT
Study - to investigate migalastat HCl monotherapy in patients
with Fabry's disease. Data from FACET study is expected in the
second quarter this year and the top-line data from the ATTRACT
study is expected in the second half of 2014.
We note that the Amicus-Glaxo collaboration for migalastat HCl
dates back to 2010. This agreement was amended in Nov 2013. As
per the agreement, Amicus will have the sole worldwide rights to
develop and commercialize migalastat HCl (both as monotherapy and
in combination with ERT) for Fabry's disease.
Amcius currently carries a Zacks Rank #2 (Buy). Better-ranked
Lannett Company, Inc.
). Both these stocks carry a Zacks Rank #1 (Strong Buy).
ENDOCYTE INC (ECYT): Free Stock Analysis
AMICUS THERAPT (FOLD): Free Stock Analysis
GLAXOSMITHKLINE (GSK): Free Stock Analysis
LANNETT INC (LCI): Free Stock Analysis Report
To read this article on Zacks.com click here.